AC
UTHR icon

Argentiere Capital’s United Therapeutics UTHR Stock Holding History

Argentiere Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-116,152
Closed -$13.6M – 47
2017
Q3 		$13.6M Buy
116,152
+38,195
+49% +$4.88M 5.24% 4
2017
Q2 		$10.1M Sell
77,957
-1,410
-2% -$176K 3.39% 8
2017
Q1 		$10.7M Buy
+79,367
New +$12M 4.31% 8

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Argentiere Capital's UTHR Position: Q4 2017 in Review

Argentiere Capital sold out of United Therapeutics (UTHR) in Q4 2017, closing a stake of 116,152 shares — an estimated $13.6M sold.

Argentiere Capital first reported a position in UTHR in Q1 2017 and held it in 3 quarters. The position peaked at $13.6M in Q3 2017. 400 funds tracked by Wall St. Rank hold UTHR as of Q4 2017.

  • Argentiere Capital reported no remaining United Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Argentiere Capital sold 116,152 United Therapeutics shares in Q4 2017, an estimated $13.6M.
  • Argentiere Capital first reported a position in United Therapeutics in Q1 2017 and held it in 3 quarters.
  • Argentiere Capital's United Therapeutics position peaked at $13.6M in Q3 2017.
  • 400 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2017.

Based on Argentiere Capital's 13F filing for Q4 2017, filed 14 Feb 2018.